hoxa13b Antibody

What is HOXA13b and how does it differ from other HOX proteins?

HOXA13b belongs to the homeobox family of transcription factors that play critical roles in embryonic development and tissue differentiation. It is a sequence-specific, AT-rich binding transcription factor that provides cells with positional identities on the anterior-posterior axis . Unlike other HOX proteins, HOXA13b has specific functions in limb and urogenital tract development. The antibodies against this protein recognize specific amino acid sequences, with many commercial antibodies targeting regions such as AA 332-388 in human HOXA13 .

What are the primary applications for HOXA13b antibodies in research?

HOXA13b antibodies serve multiple research applications including:

• Western Blotting (WB): Detection of protein expression levels in cell lysates

• Immunohistochemistry (IHC): Localization in tissue sections (both frozen and paraffin-embedded)

• Immunofluorescence (IF): Cellular localization studies

• ELISA: Quantitative protein detection

• Immunocytochemistry (ICC): Subcellular localization in cultured cells

• CUT&RUN (Cleavage Under Targets and Release Using Nuclease): Chromatin profiling

These applications have been validated with dilution ranges typically between 1:100-5000 depending on the specific application and antibody formulation .

How should researchers select the appropriate HOXA13b antibody for their experiments?

Selection should be based on:

• Target epitope: Consider whether the experiment requires detection of specific domains or full-length protein

• Host species: Select based on compatibility with other antibodies in multi-labeling experiments

• Validated applications: Ensure the antibody is validated for your specific application

• Clonality: Polyclonal antibodies often provide higher sensitivity while monoclonals offer greater specificity

• Species reactivity: Confirm cross-reactivity with your experimental model (human, mouse, rat, etc.)

Most commercially available antibodies have predicted reactivity across multiple species including mouse, rat, cow, sheep, pig, horse, chicken, and rabbit due to the high conservation of HOX proteins .

What are the optimal dilution ranges for HOXA13b antibodies in different applications?

Based on validated protocols, the following dilution ranges are recommended:

These ranges should be optimized for each specific antibody and experimental system .

What is the recommended protocol for immunohistochemical detection of HOXA13b in tissue samples?

For optimal IHC detection of HOXA13b:

• Fixation: Use 10% neutral buffered formalin for paraffin sections or 4% PFA for frozen sections

• Antigen retrieval: Perform heat-induced epitope retrieval using citrate buffer (pH 6.0)

• Blocking: Block with 5-10% normal serum from the same species as the secondary antibody

• Primary antibody: Apply HOXA13b antibody at 1:200-400 dilution and incubate overnight at 4°C

• Secondary detection: Use appropriate HRP-conjugated secondary antibody

• Visualization: Develop with DAB substrate and counterstain with hematoxylin

• Controls: Include both positive controls (tissues known to express HOXA13b) and negative controls (primary antibody omitted)

Similar to protocols used for HOX family proteins, nuclear staining should be prominent in epithelial cells of certain tissues .

How can researchers validate the specificity of their HOXA13b antibody?

Comprehensive validation should include:

• Western blot analysis: Confirm single band at the expected molecular weight (approximately 39 kDa)

• Knockout/knockdown controls: Compare staining between wild-type and HOXA13b-deficient samples

• Peptide competition: Pre-incubate antibody with immunizing peptide to confirm specific binding

• Multiple antibody comparison: Use antibodies targeting different epitopes of HOXA13b

• Recombinant protein controls: Test against purified HOXA13b protein

• Cross-reactivity testing: Evaluate potential cross-reactivity with other HOX family members

Rigorous validation is critical as cross-reactivity with other HOX family members can occur due to sequence homology .

How are HOXA13b antibodies being used to investigate cancer mechanisms?

HOXA13b antibodies are instrumental in cancer research through several applications:

• Expression profiling: Identifying HOXA13 overexpression in various cancers similar to esophageal squamous cell carcinoma where HOXA13 expression correlates with poor patient survival

• Mechanistic studies: Investigating how HOXA13 promotes cancer cell growth through immunohistochemical detection in patient samples

• Prognostic marker validation: Using IHC with HOXA13 antibodies to evaluate its potential as a prognostic biomarker, as demonstrated in studies where HOXA13 expression was associated with shorter disease-free survival

• Tumor microenvironment studies: Examining HOXA13 expression patterns in tumor versus normal adjacent tissue

• Functional studies: Following HOXA13 expression changes after experimental manipulations such as knockdown experiments

These applications can be extended to HOXA13b research with appropriate antibody selection.

What techniques combine HOXA13b antibodies with chromatin studies to investigate gene regulation?

Advanced chromatin studies utilizing HOXA13b antibodies include:

• Chromatin Immunoprecipitation (ChIP): Maps genome-wide binding sites of HOXA13b to identify target genes

• CUT&RUN: Provides higher resolution than ChIP with lower background, validated for HOXA13 antibodies

• ChIP-seq: Combines ChIP with next-generation sequencing for genome-wide binding profiles

• ChIP-qPCR: Quantifies binding to specific genomic regions

• CUT&Tag: In situ tethering of enzyme to antibody-bound factors for chromatin profiling

• Re-ChIP: Sequential ChIP to detect co-occupancy with other transcription factors

• ChIP-mass spectrometry: Identifies protein complexes associated with HOXA13b

When implementing these techniques, researchers should optimize antibody concentration (typically 1:100 dilution for CUT&RUN) and include appropriate controls to validate specificity of binding events.

How can researchers employ HOXA13b antibodies in developmental biology studies?

In developmental biology, HOXA13b antibodies enable:

• Spatiotemporal expression analysis: Tracking expression patterns during embryonic development

• Lineage tracing: Identifying cell populations expressing HOXA13b during tissue specification

• Functional studies: Examining phenotypic consequences following perturbation of HOXA13b expression

• Transgenic model validation: Confirming genetic modifications in HOXA13b knock-in/knockout models

• Organoid research: Investigating HOXA13b's role in three-dimensional tissue organization

Similar to studies on HOXA13 in Barrett's esophagus, researchers can use antibodies to investigate how abnormal expression of developmentally restricted transcription factors contributes to disease pathogenesis .

What are common problems encountered with HOXA13b antibodies and how can they be resolved?

When working with HOXA13b antibodies, nuclear localization should be evident as observed with other homeobox proteins .

What controls should be included when using HOXA13b antibodies?

Every experiment should include:

• Positive tissue controls: Tissues known to express HOXA13b (e.g., developing limb buds, genital tubercle)

• Negative tissue controls: Tissues known not to express HOXA13b

• Technical negative controls: Omission of primary antibody

• Isotype controls: Non-specific IgG from the same species as the primary antibody

• Peptide competition controls: Antibody pre-absorbed with immunizing peptide

• Genetic controls: When available, tissues from knockout models

• Cell line controls: Cell lines with known HOXA13b expression levels (similar to validated LNCaP cells for HOXB13)

These controls help distinguish specific from non-specific signals and validate experimental findings.

How should researchers address cross-reactivity with other HOX family proteins?

To minimize and identify cross-reactivity:

• Epitope selection: Choose antibodies targeting unique regions with low homology to other HOX proteins

• Western blot validation: Confirm single band at expected molecular weight (39 kDa for HOXA13)

• Parallel testing: Compare staining patterns with antibodies against related HOX proteins

• Validation in overexpression systems: Test specificity in cells overexpressing specific HOX proteins

• RNA correlation: Correlate protein detection with mRNA expression data

• Multiple antibody approach: Use antibodies targeting different epitopes to confirm findings

• Pre-absorption testing: Pre-incubate with recombinant proteins of related HOX family members

Cross-reactivity is particularly important to address given the high sequence similarity among HOX family members.

How are HOXA13b antibodies being utilized in single-cell techniques?

Emerging single-cell applications include:

• Single-cell Western blotting: Detecting HOXA13b expression heterogeneity within cell populations

• Mass cytometry (CyTOF): Conjugating HOXA13b antibodies with metal isotopes for high-dimensional analysis

• Single-cell immunofluorescence: Combined with digital image analysis for quantitative expression profiling

• Imaging mass cytometry: Spatial analysis of HOXA13b expression in tissue sections at single-cell resolution

• Proximity ligation assay (PLA): Detecting protein-protein interactions involving HOXA13b

• CODEX multiplexed imaging: Simultaneous detection of HOXA13b and multiple markers

• scRNA-seq validation: Confirming protein expression of transcriptional findings

These techniques allow researchers to investigate heterogeneity in HOXA13b expression and function at unprecedented resolution.

What are the considerations for using HOXA13b antibodies in therapeutic development research?

Researchers investigating therapeutic applications should consider:

• Epitope accessibility: Ensure the target epitope is accessible in living systems

• Internalization potential: Evaluate whether antibodies are internalized by target cells

• Functional modulation: Assess whether antibodies can modulate HOXA13b function

• Species cross-reactivity: Confirm reactivity across species for translational studies

• In vivo stability: Test stability in physiological conditions

• Conjugation compatibility: Determine compatibility with therapeutic payloads

• Off-target effects: Comprehensively evaluate cross-reactivity with other proteins

Similar to research on HOXA13's role in cancer promotion, therapeutic approaches may target HOX proteins to inhibit tumor growth .

How can researchers use HOXA13b antibodies in combination with other techniques to understand gene regulatory networks?

Integrated approaches include:

• ChIP-seq + RNA-seq: Correlate binding sites with transcriptional changes

• CUT&RUN + ATAC-seq: Compare transcription factor binding with chromatin accessibility

• Co-immunoprecipitation + mass spectrometry: Identify HOXA13b protein interaction partners

• Chromatin conformation capture (Hi-C) + ChIP: Link long-range chromatin interactions with HOXA13b binding

• CRISPR screening + immunostaining: Systematically identify genes affecting HOXA13b expression

• Proteomics + antibody validation: Confirm antibody specificity with mass spectrometry

• Reporter assays + ChIP: Validate functional significance of binding sites

These integrated approaches, similar to those used in studying HOXA13's role in Barrett's esophagus , provide comprehensive insights into HOXA13b function in development and disease.